LLY Stock: Earnings Deep Dive — Q1 2026 Earnings Analysis

Описание: Chapters
0:00 The Eli Lilly Story
3:57 Earnings Overview
8:29 What the Street Thinks

Eli Lilly and Company just reported Q1 2026 earnings — earnings deep dive.
We break down what went wrong and whether LLY can recover.

🔔 Subscribe for weekly deep dives on every Russell 1000 earnings report: https://www.youtube.com/@ChargedAlpha...

📊 Key Financial Highlights:


📈 Free stock screening tools — no signup, no paywall:
https://chargedalpha.com

🎧 Also available as a podcast:
https://chargedalpha.podbean.com

#stocks #LLY #earnings #healthcare #investing #stockmarket #earningsseason #wallstreet #EliLillyandCompany

---
Financial data and charts: Financial Modeling Prep (https://financialmodelingprep.com)

⚖️ Disclaimer: This video is for informational and educational purposes only. Nothing discussed constitutes a buy, sell, or hold recommendation. All investments carry risk. Past performance does not guarantee future results. Always do your own research and consult a qualified financial advisor. Hosts may hold positions in securities discussed. This episode was researched, written, and produced using AI-assisted tools. Data sourced from public filings and may contain inaccuracies.

💊 Related: Eli Lilly competes in GLP-1 obesity and diabetes treatments against Novo Nordisk (NVO), with Amgen (AMGN) and Viking Therapeutics (VKTX) as emerging challengers. CEO David Ricks's tirzepatide franchise — Mounjaro (diabetes) and Zepbound (obesity) — is on track for $20B+ in combined annual revenues by 2028. The donanemab Alzheimer's approval adds a second mega-blockbuster platform. At 55x forward earnings, the market prices LLY as a generational compounder — but any pipeline failure or manufacturing constraint creates an outsized drawdown risk. Manufacturing capacity expansion at Lebanon, Indiana and European sites is the #1 execution variable for the next 18 months.